The Liu Center: Pulmonary Hypertension

Current Treatment Protocols

We have treated hundreds of patients with PAH with long-term intravenous prostacyclin, treprostinil, sildenafil, tadalafil, bosentan, ambrisentan, iloprost, riociguat, macitentan, and more. We accept referrals from all sources and welcome any interest or questions from healthcare workers and from the general public.

A Phase 3 trial of bardoxolone for patients with PAH and connective tissue disease (CTD, such as scleroderma, systemic lupus erythematosus, rheumatoid arthritis, etc) is underway.

  • A trial of a new ACE2 analog (blocks angiotensin II) for patients with PAH is underway.
  • A trial of a new drug (mTor inhibitor) for patients with PAH is underway.
  • A trial of infused stem cells is underway.


Bardoxolone methyl oral

  • Sponsor: Reata Pharmaceuticals
  • Placebo: Yes
  • Primary Endpoint: 6-minute walk distance
  • Start Date: Enrolling

ACE2 analog

  • GSK
  • No (1-time infusion)
  • Pulmonary Vascular Resistance (PVR)
  • Enrolling